Prestige Consumer Healthcare In

Valuation Analysis

About the Company

Prestige Consumer Healthcare In en bref

Prestige Consumer Healthcare In (PBH) is currently trading at 40,95 € with a market capitalization of 1,9 Md €. The trailing P/E ratio stands at 12.01x, with a forward P/E of 9.36x. The 52-week range spans from 37,15 € to 74,35 €; the current price is 44.9% below the yearly high. Year-over-year revenue growth stands at -5.0%. The net profit margin stands at 17.48%.

💰 Dividende

Prestige Consumer Healthcare In currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

5 analystes évaluent Prestige Consumer Healthcare In (PBH) au consensus : None. L'objectif de cours moyen est de 58,23 €, soit un potentiel de +42.22% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 43,59 € à 65,38 €.

Prestige Consumer Healthcare In : la thèse d'investissement en détail

Prestige Consumer Healthcare In (PBH) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

The combination of a 55.65% gross margin and 26.81% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 17.48%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue is contracting at -5% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valorisation en contexte

The PEG ratio at 1.44 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9.49x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 9.36x is meaningfully below the trailing 12.01x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 42.22% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (7.38%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Prestige Consumer Healthcare In?

Compare top-rated brokers — low fees, trusted providers, fully regulated.